TENET HEALTHCARE CORP — Form 8-K
Filed July 23, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 62/100
What the filing says
Tenet reported Q2 2026 net income of $826M ($9.84/diluted share) vs. $288M ($3.14) in Q2 2025; adjusted EBITDA of $1.304B (23.2% margin) vs. $1.121B. The company raised FY2026 adjusted EBITDA guidance to $4.83–$5.03B (midpoint $295M increase) and adjusted free cash flow to $2.725–$3.025B ($225M increase). The board authorized a $2.0B increase to the share repurchase program. YTD through June 30, 2026, the company repurchased 7.02M shares for $1.360B. Hospital segment adjusted EBITDA margin improved to 18.0% from 15.6%, and ambulatory (USPI) segment revenue grew 5.0% same-facility system-wide.
Why this rating
Strong operational outperformance driving meaningful guidance raise ($520M total EBITDA/FCF improvement) represents ~4.3% uplift to midpoint, material for $12.2B company; major share buyback ($2B) signals confidence but creates near-term neutral/positive pressure.
See more from July 23, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.